|
|
 |
|
Viewing report
|
|
|
|
European Cancer Support Therapies Market
Frost & Sullivan, Oct 2010, Pages: 69
This research service analyses the European cancer support therapies market. The base year is 2009 with forecasts running through 2016. The segments covered include: the European bisphosphonates market, European growth factors market , European anti-emetics market. It analyses market drivers, restraints and challenges faced by industry participants. Revenue forecasts and pipeline analysis has been discussed. In addition, it provides decision support databases which is a collection of multiple tables that cover a sector's demand, supply, select customer demographics and pertinent economic measurements.
This research service titled European Cancer Support Therapies Market analyses market drivers, restraints and challenges faced by industry participants. Revenue forecasts and pipeline analysis have been discussed. The following segments are covered in this research: bisphosphonates, anti-emetics and growth factors.
Market Overview
Deleterious Side Effects of Existing Chemotherapy Regimes, Coupled with Rising Occurrence of Cancer, is Encouraging the Adoption of Cancer Support Therapies
Stringent regulatory requirements are delaying the launch of critical drugs in the oncology market. Moreover, premium pricing of products and reimbursement issues are curtailing the growth of this market. However, given the wide range of side effects that result due to cancer chemotherapy regimes, there are several different types of support therapies that can be used for treatment. This situation is opening up considerable growth opportunities for cancer support therapies.
“Heightened awareness and the need amongst patients for better quality of life, the continued side effects of existing chemotherapy regimes and the rising incidence of a number of cancers is driving the uptake of cancer support therapies,” notes the analyst of this research. “Current chemotherapeutic agents are highly cytotoxic, and destroy not only cancerous cells but also affect a number of healthy cells in the process, causing a range of side effects such as nausea, vomiting, fatigue, anemia and infections.” To deal with the side effects, current cancer treatment strategies entail the use of high-intensity chemotherapy coupled with optimum doses of support therapies.
However, the premium pricing of products, reimbursement issues and inadequate training to medical professionals in the usage of cancer support therapies are dampening market prospects. “Several patients who might require support therapies are just not in a position to afford them,” remarks the analyst. “Although reimbursement structures across Europe vary, except for Scandinavia, almost all western European countries include a significantly high component of patient co-payment. This is an increasing burden.”
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
- Bisphosphonates
- Anti-emetics
- Growth factors
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Also available
European Support Cancer Therapy
|
|
|
|
